• What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

In patients with chronic hepatitis B virus (HBV) infection who are negative for HBe antigen (HBeAg), monitoring levels of HB surface antigen (HBsAg) can predict disease progression, researchers report in the October issue of Clinical Gastroenterology and Hepatology. Most persons chronically infected with HBV clear HBeAg and enter an inactive carrier phase, characterized by low or undetectable

Read more
  • Is Combination Therapy Most Effective for HBV Infection?

Is Combination Therapy Most Effective for HBV Infection?

A significantly greater proportion of patients receiving a combination of tenofovir disoproxil fumarate (TDF) and pegylated interferon-α (peginterferon) for 48 weeks lost hepatitis B surface antigen (HBsAg), a marker of hepatitis B virus (HBV) DNA transcriptional activity, compared to patients given the standard care (peginterferon or TDF alone), researchers report

Read more
  • A New Approach to Hepatitis B Therapy?

A New Approach to Hepatitis B Therapy?

Cyclophilins are involved in multiple steps of the hepatitis B virus (HBV) life cycle in hepatocytes—cyclophilin inhibitors reduce viral replication and HBV envelope protein production and secretion, researchers report in the February issue of Gastroenterology. The cyclophilin inhibitor alisporivir, combined with the HBV polymerase inhibitor, reduces markers of HBV infection

Read more